Forskellen i antitrombocytaktivitet mellem COX- 1- hæmmende NSAID og selektive COX- 2- hæmmere kan være af klinisk betydning for patienter med risiko for udvikling af thromboemboliske hændelser.
The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and selective COX-2 inhibitors may be of clinical significance in patients at risk of thrombo-embolic events.